Breast Cancer Metastasis-Suppressor 1-Like (BRMS1L) ELISA Kit for Bovine

Principle of the Assay: This assay employs a two-site sandwich ELISA to quantitate BRMS1L in samples. An antibody specific for BRMS1L has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyBRMS1L present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for BRMS1L is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of BRMS1L bound in the initial step. The color development is stopped and the intensity of the color is measured.

Small volumes of BRMS1L elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS284919 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Breast cancer metastasis-suppressor 1-like protein (BRMS1L) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing BRMS1L. The ELISA analytical biochemical technique of the MBS284919 kit is based on BRMS1L antibody-BRMS1L antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect BRMS1L antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, BRMS1L. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).